Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
South Korea · Delayed Price · Currency is KRW 2,680.00
-15.00 (-0.56%)
At close: Jun 12, 2026
Kangstem Biotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -10,140 | -10,482 | -7,669 | -21,949 | -20,236 | -21,348 |
Depreciation & Amortization | 2,183 | 2,364 | 3,226 | 3,915 | 3,871 | 3,874 |
Loss (Gain) From Sale of Assets | -46.14 | -39.63 | -9,878 | -95.52 | 5.6 | -1,272 |
Asset Writedown & Restructuring Costs | - | - | - | 250.52 | - | - |
Loss (Gain) From Sale of Investments | -1,162 | -1,115 | 739.6 | 151.81 | 308.46 | 348.21 |
Loss (Gain) on Equity Investments | -5,814 | -5,741 | 2,477 | 720.33 | - | - |
Stock-Based Compensation | - | - | - | 274.36 | 1,059 | 862.04 |
Provision & Write-off of Bad Debts | -18.11 | - | - | -263.03 | -144.01 | -192.74 |
Other Operating Activities | -280.82 | -243.08 | -286.96 | -505 | -124.4 | 348.05 |
Change in Accounts Receivable | 160.83 | 42.3 | -122.32 | 1,109 | -198.26 | -371.57 |
Change in Inventory | 21.56 | 162.9 | -330.19 | -68.88 | 334.59 | -534.59 |
Change in Accounts Payable | -322.99 | -931.13 | 864.51 | -10.33 | -443.81 | 464.96 |
Change in Other Net Operating Assets | 591.84 | 4,306 | -8,007 | -27.07 | -3,296 | 828.26 |
Operating Cash Flow | -14,827 | -11,676 | -18,987 | -16,498 | -18,864 | -16,994 |
Capital Expenditures | -573.23 | -660.84 | -593.45 | -1,392 | -712.42 | -4,631 |
Sale of Property, Plant & Equipment | 82.84 | 82.84 | 73 | 28 | 19.36 | 2.27 |
Cash Acquisitions | -998.53 | -999.12 | - | - | - | - |
Divestitures | - | - | 1,270 | - | - | - |
Sale (Purchase) of Intangibles | -68.36 | 1.64 | - | 542.2 | -135.06 | -19.42 |
Investment in Securities | -17,302 | -22,401 | 15,084 | -1,496 | 17,103 | -22,955 |
Other Investing Activities | -121.7 | -88.94 | -90.31 | 13.66 | -39.02 | 2,828 |
Investing Cash Flow | -19,231 | -24,315 | 15,014 | -2,304 | 16,236 | -24,775 |
Long-Term Debt Issued | - | - | 3,530 | 380 | 1,100 | 1,830 |
Total Debt Issued | 37.92 | - | 3,530 | 380 | 1,100 | 1,830 |
Long-Term Debt Repaid | - | -578.08 | -2,645 | -923.48 | -1,568 | -918.89 |
Total Debt Repaid | -540.8 | -578.08 | -2,645 | -923.48 | -1,568 | -918.89 |
Net Debt Issued (Repaid) | -502.88 | -578.08 | 885.04 | -543.48 | -468.3 | 911.11 |
Issuance of Common Stock | 35,821 | 35,821 | - | 20,521 | 236.7 | 38,377 |
Other Financing Activities | -2,303 | -49.6 | -0.83 | -0 | 0.21 | -2.4 |
Financing Cash Flow | 33,016 | 35,193 | 884.21 | 19,977 | -231.4 | 39,286 |
Foreign Exchange Rate Adjustments | 0.01 | - | 0.39 | 0.07 | -1.33 | 55.47 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - | -0 |
Net Cash Flow | -1,043 | -797.43 | -3,089 | 1,175 | -2,861 | -2,427 |
Free Cash Flow | -15,400 | -12,337 | -19,581 | -17,890 | -19,576 | -21,624 |
Free Cash Flow Margin | -449.89% | -345.33% | -252.79% | -140.82% | -120.10% | -174.32% |
Free Cash Flow Per Share | -194.57 | -177.55 | -347.22 | -440.63 | -516.01 | -776.52 |
Cash Interest Paid | 534.13 | 496.35 | 433.65 | 567.02 | 364 | 211.46 |
Cash Income Tax Paid | - | -102.8 | -17.35 | 73.02 | 73.21 | -65.94 |
Levered Free Cash Flow | - | -5,687 | -13,120 | -9,991 | -13,595 | -15,281 |
Unlevered Free Cash Flow | - | -5,379 | -12,854 | -9,432 | -13,119 | -14,806 |
Change in Working Capital | 451.24 | 3,580 | -7,595 | 1,002 | -3,603 | 387.06 |